CJC-1295 No DAC: mechanism of action and potential benefits
CJC-1295 No DAC, often called modified GRF 1-29, is a short-acting analogue of growth hormone-releasing hormone. The 'No DAC' form lacks the drug-affinity complex that would otherwise extend circulation time.
99%+ HPLC purity
Batch COA records
QR vial verification
Scientific product profiles
Mechanism of action
It activates GHRH receptors on pituitary cells, increasing cyclic AMP and stimulating a pulse of growth-hormone secretion. Growth hormone then acts directly and through IGF-1 on protein turnover, lipid metabolism, bone, and connective tissues.
Potential benefits
May support physiological growth-hormone pulses
May influence protein synthesis and recovery pathways
May promote lipid mobilization
May support connective-tissue and bone metabolism
Evidence context: Its pathway is biologically plausible, but outcome data for the specific No DAC form are limited compared with its mechanistic description.
Product data and verification
DEU Peptides connects the CJC-1295 No DAC catalog entry with identity, purity, storage, and batch data. A registered QR code can confirm the product name, concentration, batch ID, vial ID, and date fields.
It activates GHRH receptors on pituitary cells, increasing cyclic AMP and stimulating a pulse of growth-hormone secretion. Growth hormone then acts directly and through IGF-1 on protein turnover, lipid metabolism, bone, and connective tissues.
What potential benefits are associated with CJC-1295 No DAC?
May support physiological growth-hormone pulses; May influence protein synthesis and recovery pathways; May promote lipid mobilization; May support connective-tissue and bone metabolism.
How strong is the evidence for CJC-1295 No DAC?
Its pathway is biologically plausible, but outcome data for the specific No DAC form are limited compared with its mechanistic description.
This scientific overview is general information and does not replace individualized medical advice, diagnosis, or treatment.